<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04145440</url>
  </required_header>
  <id_info>
    <org_study_id>MOR202C103</org_study_id>
    <nct_id>NCT04145440</nct_id>
  </id_info>
  <brief_title>Trial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN)</brief_title>
  <acronym>M-PLACE</acronym>
  <official_title>A Phase Ib/IIa, Open-Label, Multicenter Clinical Trial to Assess Safety and Efficacy of the Human Anti-CD38 Antibody MOR202 in Anti-PLA2R Antibody Positive Membranous Nephropathy (aMN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MorphoSys AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MorphoSys AG</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multicentre study to characterize the safety and efficacy of the human
      anti-CD38 antibody MOR202 in adult subjects with in Anti-PLA2R Antibody Positive Membranous
      Nephropathy (newly diagnosed/relapsed/refractory)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After treatment subjects will be observed for up to 1 year.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 15, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>2 cohorts</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety and tolerability: incidence and severity of treatment-emergent adverse events</measure>
    <time_frame>at end of treatment phase (after 6 months)</time_frame>
    <description>incidence and severity of treatment-emergent adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>effect of MOR202 on serum anti-PLA2R antibodies</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>best Immunological Response based on reduction of serum anti-PLA2R antibody titer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>immunogenicity of MOR202</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>number of subjects developing anti-MOR202 antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK profile</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>serum concentrations after multiple i.v. administrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety in the follow-up phase: incidence and severity of adverse events (AEs) in the follow-up phase</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>incidence and severity of adverse events (AEs) in the follow-up phase</description>
  </secondary_outcome>
  <other_outcome>
    <measure>clinical efficacy: effect of MOR202 treatment on reduction of proteinuria</measure>
    <time_frame>at end of treatment phase (end of cycle 6) and end of study (after 12 months)</time_frame>
    <description>number of subjects achieving a complete response or a partial response based on reduction of proteinuria</description>
  </other_outcome>
  <other_outcome>
    <measure>QoL: KDQOL-36</measure>
    <time_frame>at defined time points through study completion, last after 1 year</time_frame>
    <description>defined as score change from baseline as assessed by KDQOL-36</description>
  </other_outcome>
  <other_outcome>
    <measure>kinetics of anti-PLA2R antibody titers</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>anti-PLA2R antibody titer % change from baseline to each visit</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Glomerulonephritis, Membranous</condition>
  <condition>antiPLA2R Positive</condition>
  <arm_group>
    <arm_group_label>MOR202</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>9 doses of MOR202 will be administered as an intravenous infusion at 16 mg/kg over 6 treatment cycles at 28-days each. Dosing occurs weekly in cycle 1 (C1) and every four weeks in cycles 2-6.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MOR202</intervention_name>
    <description>9 doses of MOR202 will be administered as an intravenous infusion at 16 mg/kg over 6 treatment cycles at 28-days each, weekly in C1 and every 4 weeks C2-6.</description>
    <arm_group_label>MOR202</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Urine protein to creatinine ratio of ≥3.0 g/g (as measured from a 24 hour urine
             collection)

          -  Active anti-PLA2R antibody positive MN in need for immunosuppressive therapy (IST)
             according to investigator judgement and diagnosed on the basis of a biopsy, archival
             biopsy acquired within 5 years prior to screening is acceptable.

          -  Estimated glomerular filtration rate ≥50 ml/min/1.73m² or &gt;30 and &lt;50 ml/min/1.73m²,
             and interstitial fibrosis and tubular atrophy score of less than 25% on a renal biopsy
             obtained within the last 6 months prior to start of screening.

          -  on supportive treatment with an Angiotensin Converting Enzyme Inhibitor or an
             Angiotensin II Receptor Blocker for at least 4 weeks prior to Screening, having
             reached a stable dose.

          -  Systolic BP ≤150 mmHg and diastolic BP ≤100 mmHg

          -  Vaccinated against Pneumococcus within the last 3 years prior to date of signing
             informed consent (subjects may be vaccinated during screening to meet this criterion;
             interval to first dose of MOR202 must be at least 14 days).

          -  Cohort 1a (newly diagnosed patients): Serum anti-PLA2R antibodies ≥150.0 Response
             Units(RU)/mL determined at screening by Euroimmun ELISA.

          -  Cohort 1b, relapse subjects: Must have had complete immunological and/or clinical
             remission according to judgement of the investigator and serum anti-PLA2R antibodies
             ≥50.0 RU/mL determined at screening by Euroimmun ELISA.

          -  Cohort 2: Failure of previous therapy, i.e. subject never achieved a complete
             immunological and/or clinical remission according to judgement of the investigator.
             during or after completion of a recognized IST containing cyclosporine A, tacrolimus,
             mycophenolate-mofetil, ACTH or alkylating agents (e.g. cyclophosphamide), or
             rituximab. Serum anti-PLA2R antibodies ≥20.0 RU/mL determined at screening by the
             Euroimmun ELISA.

        Key Exclusion Criteria:

          -  Hemoglobin &lt;90 g/L.

          -  Thrombocytopenia: Platelets &lt;100.0x109/L.

          -  Neutropenia: Neutrophils &lt;1.5x109/L.

          -  Leukopenia: Leukocytes &lt;3.0x109/L .

          -  Hypogammaglobulinemia: Serum immunoglobulins ≤5.0 g/L.

          -  Secondary cause of MN (e.g. Systemic lupus erythematosus, medications, malignancies)

          -  Concomitant renal disease other than MN (e.g., diabetic renal disease, lupus
             nephritis, IgA nephropathy).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xuefei Zhou, MBBS, PhD</last_name>
    <phone>+498989927</phone>
    <phone_ext>0</phone_ext>
    <email>MOR202C103-CPL@morphosys.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Goran Babic, MD</last_name>
    <phone>+498989927</phone>
    <phone_ext>0</phone_ext>
    <email>MOR202C103-CPL@morphosys.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>O.L.V. Ziekenhuis</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Liège</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Pellegrin - Hôpital Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble - Hôpital Albert Michallon</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Claude Huriez -CHU Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Tenon Service de nephrologie</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Saint Etienne - Hôpital Nord</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Careggi</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Radboud UMC Niimegen Nephrology</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofia</name>
      <address>
        <city>Córdoba</city>
        <zip>50134</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro Majadahonda</name>
      <address>
        <city>Madrid</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>October 18, 2019</study_first_submitted>
  <study_first_submitted_qc>October 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2019</study_first_posted>
  <last_update_submitted>June 8, 2020</last_update_submitted>
  <last_update_submitted_qc>June 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glomerulonephritis</mesh_term>
    <mesh_term>Glomerulonephritis, Membranous</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

